Currently Viewing:
Newsroom
Currently Reading
clonoSEQ Assay Medicare Coverage Expanded to Include MRD in CLL
January 13, 2020 – Maggie L. Shaw
Partnership Seeks to Offer Combined Somatic, Germline Testing to Guide Cancer Treatment
January 06, 2020 – Mary Caffrey
Study Suggests Epigenetic Therapy May Help Subgroup of Patients With Marginal Zone Lymphoma
January 06, 2020 – Alison Rodriguez
Study Examines Prognostic Subsets of B Cell Receptor Immunoglobulins in CLL
January 05, 2020 – Alison Rodriguez
Top 5 Most-Watched Interviews in 2019
December 25, 2019 – AJMC Staff
Researchers Report on Use of Nanopore Technology to Detect AML Biomarkers
December 22, 2019 – Sara Karlovitch
Biomarker Use in Colorectal Cancer
December 17, 2019 – Maggie L. Shaw
The Value of Genomic Profiling for Women With Breast Cancer
December 15, 2019 – Laura Joszt
At Increasing Levels of Sensitivity, NGS-MRD Detects CLL in Bone Marrow
December 14, 2019 – AJMC Staff

clonoSEQ Assay Medicare Coverage Expanded to Include MRD in CLL

Maggie L. Shaw
clonoSEQ, from Adaptive Biotechnologies, is a next-generation sequencing assay with existing Medicare coverage to monitor for minimal residual disease (MRD) in multiple myeloma and B-cell acute lymphoblastic leukemia. The newest Medicare coverage is for chronic lymphocytic leukemia (CLL), which takes effect immediately.
clonoSEQ, from Adaptive Biotechnologies, is a next-generation sequencing assay that uses a proprietary immunosequencing platform to monitor for minimal residual disease (MRD) in multiple myeloma and B-cell acute lymphoblastic leukemia—coverage it received last year. The newest Medicare coverage is for chronic lymphocytic leukemia (CLL), meaning that clonoSEQ is now available to more than 175 million individuals with healthcare coverage under Medicare or privately.

The expanded CLL Medicare coverage takes effect immediately and was handed down after clonoSEQ was evaluated for this indication by Palmetto GBA, a Medicare Administrative Contractor that reviews the utility of diagnostic technologies for Medicare coverage.

With trial results stressing the importance of MRD in predicting long-term patient outcomes—as well as abstracts presented at this year’s American Society of Hematology Annual Meeting—the implications of clonoSEQ’s expanded coverage could be far-reaching, most notably because MRD assessment is actually a series of tests that monitor for any signs of remission, relapse, and treatment response. The results also help to determine patient care.

 

“As newer therapies emerge for CLL that can help patients achieve very deep remissions, assessment of MRD can help guide clinical care by determining a patient’s response to therapy and informing that patient’s prognosis,” stated Javier Pinilla-Ibarz, MD, PhD, senior member and head of the Lymphoma Program in the Department of Malignant Hematology at Moffit Cancer Center.

 

clonoSEQ is the only FDA-authorized MRD test for use in any lymphoid malignancy.

 

Reference

Adaptive Biotechnologies receives expanded Medicare coverage of clonoSEQ for monitoring MRD in patients with chronic lymphocytic leukemia [news release]. Seattle, WA: Adaptive Biotechnologies; January 8, 2020. investors.adaptivebiotech.com/news-releases/news-release-details/adaptive-biotechnologies-receives-expanded-medicare-coverage. Accessed January 13, 2020.

Related Articles

Patients Need More Education Regarding the Purpose of Precision Medicine Trials
At Increasing Levels of Sensitivity, NGS-MRD Detects CLL in Bone Marrow
Biomarker Use in Colorectal Cancer
Partnership Seeks to Offer Combined Somatic, Germline Testing to Guide Cancer Treatment
Blueprint Medicines' Ayvakit Approved for Rare GIST With PDGFRA Mutation
 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up